Cognition Therapeutics Inc (CGTX): who owns it and who trades it
As of Nov 12, 2026, CGTX insiders reported 3 purchases worth $32.5K in the last 12 months. The largest buyer was John Brendan Doyle (CFO), with $11.3K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cognition Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CGTX
67 funds and institutions reported CGTX shares worth $26.1M at the end of Q2 2026, about 25% of the company. The largest holder is BIOS Capital Management, LP with 6.7%.
Funds and institutions (13F) 25%Everyone else 75%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BIOS Capital Management, LP | 6.00M | 6.71% | $6.9M | No change |
| DAVENPORT & Co LLC | 4.26M | 4.77% | $4.9M | +47% |
| Vanguard Capital Management LLC | 3.44M | 3.85% | $4M | +15% |
| BlackRock, Inc. | 1.26M | 1.41% | $1.5M | +30% |
| Chescapmanager LLC | 997,029 | 1.12% | $1.1M | No change |
| Geode Capital Management, LLC | 910,006 | 1.02% | $1M | -1% |
| Renaissance Technologies LLC | 693,288 | 0.78% | $797K | -38% |
| Hilton Capital Management, LLC | 548,950 | 0.61% | $631K | No change |
| Vanguard Fiduciary Trust Co | 508,220 | 0.57% | $584K | +10% |
| CM Management, LLC | 450,000 | 0.50% | $518K | +12% |
| Dauntless Investment Group, LLC | 371,701 | 0.42% | $427K | -14% |
| Sigma Planning Corp | 362,265 | 0.41% | $417K | +7% |
| State Street Corp | 348,983 | 0.39% | $401K | +11% |
| Tocqueville Asset Management L.P. | 320,500 | 0.36% | $369K | +64% |
| UBS Group AG | 218,536 | 0.24% | $251K | +184% |
| American Financial Group Inc | 205,000 | 0.23% | $236K | No change |
| Northern Trust Corp | 178,202 | 0.20% | $205K | +6% |
| Voss Capital, LP | 175,000 | 0.20% | $201K | -12% |
| Texas Capital Bank Wealth Management Services Inc | 143,296 | 0.16% | $165K | +16% |
| Charles Schwab Investment Management Inc | 84,940 | 0.10% | $97.7K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CGTX insiders reported $32.5K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | John Brendan Doyle | CFO | Purchase | 10,000 | $1.13 | $11.3K | Form 4 |
| Apr 16, 2026 | Lisa Ricciardi | CEO | Purchase | 9,175 | $1.10 | $10.1K | Form 4 |
| Apr 16, 2026 | Anthony Caggiano | Chief Medical Officer | Purchase | 10,000 | $1.11 | $11.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John Brendan Doyle | Chief Financial Officer | $11.3K | – | Apr 16, 2026 |
| Anthony Caggiano | Chief Medical Officer | $11.1K | – | Apr 16, 2026 |
| Lisa Ricciardi | CEO & President, Director | $10.1K | – | Apr 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CGTX short interest
Moderate short interest. 7.3% of CGTX shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.92M CGTX shares were sold short, 7.3% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 453,080 shares, buying them all back would take about 15.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.92M | 7.27% | -2% | 453,080 | 15.3 |
| Oct 15, 2026 | 7.04M | 7.40% | -7% | 707,897 | 9.9 |
| Sep 30, 2026 | 7.58M | 7.97% | -2% | 455,659 | 16.6 |
| Sep 15, 2026 | 7.74M | 8.14% | -2% | 342,552 | 22.6 |
| Aug 31, 2026 | 7.86M | 8.27% | +10% | 386,413 | 20.3 |
| Aug 14, 2026 | 7.13M | 7.49% | -20% | 708,921 | 10.1 |
| Jul 31, 2026 | 8.93M | 9.99% | -8% | 422,793 | 21.1 |
| Jul 15, 2026 | 9.68M | 10.83% | +37% | 2.01M | 4.8 |
| Jun 30, 2026 | 7.07M | 7.91% | -6% | 3.17M | 2.2 |
| Jun 15, 2026 | 7.51M | 8.41% | +17% | 1.30M | 5.8 |
| May 29, 2026 | 6.42M | 7.19% | -17% | 832,444 | 7.7 |
| May 15, 2026 | 7.76M | 8.68% | -3% | 804,072 | 9.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cognition Therapeutics company events
Cognition Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Nov 5, 2026.
- Nov 5, 2026ListingThe Company received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required… Filing
- Oct 22, 2026AnnouncementResults of Operations and Financial Condition. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 24, 2026AnnouncementResults of Operations and Financial Condition. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- Jun 4, 2026AnnouncementShared information with investors. Filing
- May 21, 2026AnnouncementCognition Therapeutics, Inc. issued a press release announcing the completion of its meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies patients with psychosis. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AnnouncementCognition Therapeutics, Inc. issued a press release announcing its plans to advance development of zervimesine for the treatment of dementia with Lewy bodies psychosis. Filing
- Jan 27, 2026AnnouncementCognition Therapeutics, Inc. issued a press release announcing the completion of its Tye C meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies. Filing
- Dec 18, 2025AgreementCognition Therapeutics, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC, pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share, through or to Jefferies, as sales agent or principal. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cognition Therapeutics financials
Famous investors that hold CGTX
1 of the 50 well-known investors we track reported holding CGTX in their latest 13F filing. The largest position is Jim Simons's, worth $564K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 587,171 | $564K | 0.0% | -15% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Cognition Therapeutics Inc (CGTX) stock
Who owns the most CGTX stock?
The largest reported owner of Cognition Therapeutics Inc (CGTX) is BIOS Capital Management, LP, with 6.7% of the company. In total, 67 funds and institutions reported holding CGTX at the end of Q2 2026, together about 25% of the shares. See the largest owners.
Are CGTX insiders buying or selling?
In the last 12 months, CGTX insiders reported 3 open-market purchases worth $32.5K and no sales. The latest trade was on Apr 16, 2026. See every trade.
What is the short interest in CGTX?
As of Oct 30, 2026, 6.92M CGTX shares were sold short, 7.3% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 453,080 shares, buying them all back would take about 15.3 trading days (days to cover). See the history.
Which famous investors hold CGTX?
1 of the 50 well-known investors we track reported CGTX in their latest 13F filing, including Jim Simons. The largest position is worth $564K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.